The Drug-Induced Respiratory Disease Website and App

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.e Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.h Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.k Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.l Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.s A mass or masses

I. Interstitial/parenchymal lung disease

I.u Relapsing or migrating pneumonitis/pneumonia (see also Id)

I. Interstitial/parenchymal lung disease

I.w Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)

I. Interstitial/parenchymal lung disease

I.z An area or areas of consolidation

I. Interstitial/parenchymal lung disease

I.aa Delayed ILD, -pneumonitis, -fibrosis

I. Interstitial/parenchymal lung disease

I.ao Pulmonary infiltrates

I. Interstitial/parenchymal lung disease

I.at Amiodarone pulmonary toxicity - Amiodarone lung

I. Interstitial/parenchymal lung disease

I.ax Chronic pneumonitis

I. Interstitial/parenchymal lung disease

I.ay Unilateral interstitial lung disease

II. Pulmonary edema - Acute lung injury - ARDS

II.b ARDS - Acute lung injury

II. Pulmonary edema - Acute lung injury - ARDS

II.l Postoperative ARDS

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.c Hemoptysis

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.d Cough (lone)

IV. Airway involvement

IV.r Airway pigmentation (black, bluish, petechial)

V. Pleural and/or pericardial involvement

V.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

V. Pleural and/or pericardial involvement

V.c Pleural thickening - Fibrothorax

V. Pleural and/or pericardial involvement

V.d Pleural/pericardial effusion, ANA positive (DI lupus)

V. Pleural and/or pericardial involvement

V.t The apical cap

VI. Pulmonary vasculopathy

VI.a Pulmonary embolism - Venous thrombosis/thromboembolism

VI. Pulmonary vasculopathy

VI.i Acute pulmonary hypertension

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.a Angioedema (may cause UAO, asphyxia and death)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.d Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.ai Acute respiratory failure (hypoxemia, acidosis) from myxedema (-coma)

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.q Systemic inflammatory response

XI. Miscellaneous

XI.c Pleuritic chest pain

XI. Miscellaneous

XI.f Bluish, pseudocyanotic skin discoloration

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XII. Cardiovascular involvement / toxicity

XII.e Takotsubo (stress) cardiomyopathy

XII. Cardiovascular involvement / toxicity

XII.l Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

XII. Cardiovascular involvement / toxicity

XII.n Cardiovascular collapse - Cardiogenic shock - Hypotension

XII. Cardiovascular involvement / toxicity

XII.p QTc prolongation

XII. Cardiovascular involvement / toxicity

XII.t Torsades de pointe

XII. Cardiovascular involvement / toxicity

XII.af Coronary vasospasm - Vasospastic angina

XII. Cardiovascular involvement / toxicity

XII.au Heart failure (thyrotoxicosis-, thyroid storm-mediated)

XV. Pathology

XV.a Path: NSIP-cellular pattern (see also Ia, Ib)

XV. Pathology

XV.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

XV. Pathology

XV.c Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XV. Pathology

XV.d Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

XV. Pathology

XV.f Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XV. Pathology

XV.g Path: Alveolar hemorrhage (see also IIIa)

XV. Pathology

XV.h Path: NSIP-fibrotic pattern

XV. Pathology

XV.i Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)

XV. Pathology

XV.j Path: Pulmonary fibrosis (UIP-pattern)

XV. Pathology

XV.k Path: Desquamative interstitial pneumonia (DIP-pattern)

XV. Pathology

XV.m Path: Lymphoid hyperplasia (including nodular- or a lymphocytic interstitial pneumonia pattern)

XV. Pathology

XV.o Path: Endogenous lipoid pneumonia (phospholipidosis)

XV. Pathology

XV.r Path: Smudged geographic necrosis

XV. Pathology

XV.ao Path: Pleuritis, pleural fibrosis

XV. Pathology

XV.bt Path: Histiocytic proliferation

XV. Pathology

XV.co Path: Foamy inclusions in alveolar macrophages and/or in other lung cells

XV. Pathology

XV.dc Path: Acute eosinophilic pneumonia pattern (see also under XVIb)

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVI. Imaging

XVI.i Imaging: An area or areas of involvement with a recognizable anatomic distribution

XVI. Imaging

XVI.j Imaging: Wandering (migratory) pulmonary opacities

XVI. Imaging

XVI.n Imaging: Intralobular septal thickening - Crazy paving

XVI. Imaging

XVI.s Imaging: An area or areas of involvement with high attenuation numbers or metallic density

XVI. Imaging

XVI.w Imaging: Lung nodule or nodules

XVI. Imaging

XVI.aa Imaging: Nodules, mass or masses with a central area of low attenuation (see also under XVIaa)

XVI. Imaging

XVI.ab Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XVI. Imaging

XVI.ay Imaging: Asymmetrical, predominantly unilateral involvement

XVI. Imaging

XVI.az Imaging: Solitary pulmonary nodule

XVI. Imaging

XVI.bj Imaging: Atelectasis (a combination of increased density and volume loss. Typically lobar)

XVI. Imaging

XVI.bq Imaging: A pattern consistent with pleuroparenchymal fibroelastosis

XVI. Imaging

XVI.bt Imaging: A subsolid lung nodule or nodules

XVI. Imaging

XVI.bx Imaging: Waxing and waning nodules

XVI. Imaging

XVI.ca Imaging: Disseminated patchy pulmonary opacities

XVII. Infections & related conditions

XVII.e Pneumocystis jiroveci pneumonia

XVIII. Distinctive patterns - 'Eye-catchers'

XVIII.b Eye catcher: Electron-dense area or areas of consolidation on unenhanced chest CT

XVIII. Distinctive patterns - 'Eye-catchers'

XVIII.j Eye-catcher: Avid lung uptake on 18F-PET-CT

XVIII. Distinctive patterns - 'Eye-catchers'

XVIII.k Eye-catcher: An electron-dense liver on unenhanced CT

XVIII. Distinctive patterns - 'Eye-catchers'

XVIII.p Eye-catcher: An electron-dense ('white') thyroid

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.a BAL: An excess proportion of lymphocytes

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.b BAL: An excess proportion of neutrophils

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.c BAL: An excess proportion of eosinophils

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.e BAL: Stainable iron in macrophages

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.f BAL: Foamy macrophages

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.m BAL: A normal cell differential

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.p BAL: Lamellar bodies in AM on EM

XXVIII. Pulmonary physiology - PFTs

XXVIII.c Platypnea-orthodeoxia

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.e Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.l Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.x Pleuroparenchymal fibroelastosis (PPFE)

V. Pleural and/or pericardial involvement

V.b Eosinophilic pleural effusion

V. Pleural and/or pericardial involvement

V.d Pleural/pericardial effusion, ANA positive (DI lupus)

V. Pleural and/or pericardial involvement

V.h Chylothorax

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.j Myopathy-Myositis-Polymyositis (see also under Xba)

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XV. Pathology

XV.a Path: NSIP-cellular pattern (see also Ia, Ib)

XV. Pathology

XV.o Path: Endogenous lipoid pneumonia (phospholipidosis)

XV. Pathology

XV.ap Path: Pleuroparenchymal fibrosis/fibroelastosis (PPFE)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.d Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.u Relapsing or migrating pneumonitis/pneumonia (see also Id)

I. Interstitial/parenchymal lung disease

I.x Pleuroparenchymal fibroelastosis (PPFE)

I. Interstitial/parenchymal lung disease

I.aq Interstitial Pneumonitis with Autoimmune Features (IPAF)

I. Interstitial/parenchymal lung disease

I.ar The association of ILD and myositis

IV. Airway involvement

IV.d Cough (lone)

V. Pleural and/or pericardial involvement

V.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

V. Pleural and/or pericardial involvement

V.b Eosinophilic pleural effusion

V. Pleural and/or pericardial involvement

V.d Pleural/pericardial effusion, ANA positive (DI lupus)

V. Pleural and/or pericardial involvement

V.h Chylothorax

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.a Angioedema (may cause UAO, asphyxia and death)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.ac Myositis of the respiratory muscles (May lead to respiratory muscle paralysis)

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.j Myopathy-Myositis-Polymyositis (see also under Xba)

X. Systemic/Distant conditions, syndromes and reactions

X.ba Rhabdomyolysis (see also under Xj)

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XII. Cardiovascular involvement / toxicity

XII.ab Pericardial fat necrosis

XV. Pathology

XV.c Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XV. Pathology

XV.d Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

XV. Pathology

XV.h Path: NSIP-fibrotic pattern

XV. Pathology

XV.o Path: Endogenous lipoid pneumonia (phospholipidosis)

XV. Pathology

XV.ap Path: Pleuroparenchymal fibrosis/fibroelastosis (PPFE)

XV. Pathology

XV.co Path: Foamy inclusions in alveolar macrophages and/or in other lung cells

XVI. Imaging

XVI.bx Imaging: Waxing and waning nodules

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.f BAL: Foamy macrophages